Introduction & Objectives
68Ga PSMA-PET/CT is a novel imaging modality introduced to improve diagnosis and staging of advanced prostate cancer. Due to its naïve nature, robust sensitivity and specificity data outlining 68Ga PSMA-PET positive scans are not available. We aimed to systematically review the current literature and perform a meta-analysis of the reported sensitivity and specificity of 68Ga PSMA-PET.
Material & Methods
We performed critical reviews of MEDLINE, EMBASE, ScienceDirect, Cochrane Libraries and Web of Science databases in April 2016 according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. Quality assessment was performed using Quality Assessment if Diagnostic Accuracy Studies-2 tool. Summary sensitivity and specificity values were obtained by fitting bivariate hierarchical regression models.
Five studies reported on the predictive ability of PSMA-PET imaging with respect to histology proven disease, four on a per-patient basis and four on a per-lesion basis. On per-lesion analysis, the summary sensitivity is 80% and specificity is 97%. On per-patient analysis, the summary sensitivity and specificity is 86% though with the low numbers reported in the contributing studies, the confidence intervals are especially wide.
To date, pooled data has identified favourable sensitivity and specificity profiles compared to historical values of alternate PET imaging techniques.